Adam Gregory

Adam is an experienced patent attorney with a focus on building and managing global patent portfolios, particularly in the fields of cell and gene therapy, antibody technology, immunotherapy, and emerging sectors such as longevity technology and cellular agriculture. With clients spanning Singapore, Europe, and the US, he works closely with start-ups, academic institutions, governmental organisations, and multinational corporations, offering tailored IP strategies that align with commercial goals like securing investment or driving acquisition opportunities. His areas of technical expertise include immunology, molecular and cellular biology, cancer, neurology, infectious and autoimmune disease, cell culture, stem cell technology and genetic engineering.

Adam is known for taking a proactive, client-focused approach to IP strategy. He invests time in understanding not only the science behind his clients' technologies but also their broader commercial objectives. Whether it’s helping biotech ventures prepare for funding rounds or assisting larger biopharma companies navigate the complexities of drafting and multijurisdictional prosecution of patent families for key programmes, Adam is dedicated to ensuring that his clients' IP portfolios support their long-term growth and commercial success.

Adam has a D.Phil. in Clinical Medicine and a first class undergraduate degree in Biological Sciences, both from the University of Oxford. He joined Mewburn Ellis LLP in 2012, qualifying as a Chartered Patent Attorney and a European Patent Attorney in 2016, and became a Partner in 2020.

Global Client Base and Biotech Community

Adam works with a diverse range of clients across the biotechnology sector, from early-stage start-ups and academic institutions to large multinational biopharma companies. Based in Singapore, Europe, and the US, his clients include innovative biotechs, large multinational biopharma companies and academic/governmental institutions. Adam is also a trusted advisor to venture capital firms, providing critical insights into IP strength when evaluating investment opportunities and helping them assess the robustness of IP positions. His strategic consulting extends to freedom-to-operate (FTO) assessments and identifying opportunities for portfolio expansion.

Recognised as a key figure in Singapore’s vibrant life sciences ecosystem, Adam has become a go-to advisor for biotech start-ups and spin-outs, helping them to devise and execute their IP strategies. In addition to his client work, Adam is deeply embedded in Singapore’s biotech community, and regularly participates in workshops, seminars, and podcasts, sharing his expertise in IP strategy and innovation management.

Key Projects and Contributions

• Enleofen Bio: Adam played a pivotal role in developing the patent portfolio for Enleofen Bio, a company focused on treating fibroinflammatory diseases. This portfolio was instrumental in securing a landmark deal with Boehringer Ingelheim, which could ultimately exceed USD 1 billion in upfront and milestone payments (the largest ever deal for a Singapore-based biotech).
  
  
• Hummingbird Bioscience: As the lead patent advisor for Hummingbird Bioscience, a company specialising in precision therapeutics for hard-to-drug targets, Adam has been instrumental in drafting and managing their patent portfolio, and has supported Hummingbird through multiple funding rounds, and several high-value licensing deals.
  
  
• Large Biopharma Clients: Adam works at the forefront of patent strategy for several large biopharma companies, helping them protect innovations in antibody technologies, cell therapies and gene therapies. His extensive work includes patent drafting and prosecution, as well as strategic advice for navigating the complexities of regulatory and market dynamics in these emerging fields.
  
  
• Future Food Tech VC: Adam has also supported a Future Food Tech VC company with its IP due diligence processes. His work has involved reviewing intellectual property portfolios for several companies in the cellular agriculture and alternative protein space, helping the VC firm to evaluate investment opportunities in this fast-moving sector.
  

Industry Recognition and Thought Leadership

Adam is regularly invited to contribute to thought leadership initiatives within the biotech and IP fields. Adam is deeply engaged with the Singapore biotech community, and is frequently called upon to share his expertise. His passion for advancing life sciences innovation is evident in his ongoing commitment to supporting the commercialisation of breakthrough technologies through effective IP strategy. He also enjoys mentoring young professionals entering the industry and is dedicated to fostering the next generation of biotech entrepreneurs.

Adam has been listed as a "Key Lawyer" in the  2021, 2023, 2024 and 2025 editions of The Legal 500, and as a Recommended Individual in the 2025 edition of IAM Patent 1000.

Client Testimonials

"Very knowledgeable with excellent understanding of the subject matter being discussed. Attention to detail and clients' wishes. A standout partner is Adam Gregory." – Client testimonial, Legal 500 2025 edition.

“I have worked with Adam Gregory for many years, and their expertise has been instrumental in building and protecting Hummingbird Bioscience’s IP position. Adam and his team have drafted and managed Hummingbird’s entire patent portfolio, supported us through multiple funding rounds and helped guide the IP strategy behind key transactions. Throughout every stage, Adam has been proactive, strategic and commercially-astute, providing excellent advice that has enabled Hummingbird to scale and close complex deals with confidence. I cannot recommend them highly enough.” – Jovina Low, Senior Director of Intellectual Property, Hummingbird Bioscience.

“I’ve worked with Adam for over a decade and at several of Singapore’s top biotechs. Adam’s work has been extremely important in building robust, investable patent portfolios at each of these companies. He combines deep technical understanding of cutting-edge biotechnologies and a clear sense of commercialisation strategy, together with very deep expertise and experience in patent drafting and prosecution strategy. He ensures that each company's IP position is aligned with the expectations of the company’s Board of Directors and its business goals.” – Guy Heathers, Chief Business Officer, Albatroz Therapeutics.

"Working with Adam and the Mewburn Ellis team has given us real peace of mind. From day one, they’ve understood the nuances of our science and translated that into an IP strategy that reflects the value and potential of our technologies. Their attention to detail, responsiveness, and ability to think several steps ahead has been critical for us as we’ve grown and engaged with investors and partners globally." – Yann Chong Tan, CEO, Nuevocor.